Long‐term outcomes of metastasis‐directed stereotactic body radiation therapy in metastatic nasopharyngeal carcinoma
Cancer Medicine · 2024-01 · 13 (1)
DOI: 10.1002/cam4.6764 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 26.12.2023. Verfasst von Jiangping Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Oncology and Department of Radiation Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital,…. Hauptthemen laut MEDLINE: Radiosurgery, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The study aims to evaluate the outcomes of metastasis‐directed stereotactic body radiation therapy (SBRT) in metastatic nasopharyngeal carcinoma (mNPC).
Methods
We reviewed all SBRT conducted in patients with mNPC in our institution between 2013 and 2022. Systemic therapy was performed with chemotherapy with or without anti‐programmed death‐1 (PD‐1) therapy. Local treatment delivered with ablative purpose in stereotactic setting with dose/fraction ≥5 Gy was evaluated. Kaplan–Meier analyses were used to determine the rates of local control (LC), progression‐free survival (PFS), and overall survival (OS). Univariate and multivariate analyses were performed by Cox regression.
Results
A total of 54 patients with 76 metastatic sites receiving SBRT were analyzed. Median follow‐up was 49 months. The 3‐year LC, PFS, and OS rates were 89.1%, 29.4%, and 57.9%, respectively. Adding a PD‐1 inhibitor to SBRT tended to prolong median OS (50.1 vs. 32.2 months, p = 0.068). Patients receiving a biological effective dose (BED, α/β = 10) ≥ 80 Gy had a significantly longer median OS compared to those who received a lower dose (not reached vs. 29.5 months, p = 0.004). Patients with oligometastases (1–5 metastases) had a better median OS (not reached vs. 29.5 months, p < 0.001) and PFS (34.3 vs. 4.6 months, p < 0.001). Pretreatment EBV‐DNA and maintenance therapy were also significant predictors for OS.
Conclusions
Metastatic NPC patients could benefit from metastases‐directed SBRT in combination with systemic therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Head and Neck Oncology and Department of Radiation Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
- Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospita…
ORCID-Profile: Jinlan He
Zitieren
APA
Yang, J., Liao, W., Su, S., Zeng, N., Zhang, S., He, J., & Chen, N. (2024). Long‐term outcomes of metastasis‐directed stereotactic body radiation therapy in metastatic nasopharyngeal carcinoma. Cancer Medicine, 13(1). https://doi.org/10.1002/cam4.6764
Vancouver
Yang J, Liao W, Su S, Zeng N, Zhang S, He J, et al. Long‐term outcomes of metastasis‐directed stereotactic body radiation therapy in metastatic nasopharyngeal carcinoma. Cancer Medicine. 2024;13(1). doi:10.1002/cam4.6764
BibTeX
@article{Yang2024,
author = {Yang, Jiangping and Liao, Wenjun and Su, Shitong and Zeng, Ni and Zhang, Shichuan and He, Jinlan and Chen, Nianyong},
title = {Long‐term outcomes of metastasis‐directed stereotactic body radiation therapy in metastatic nasopharyngeal carcinoma},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {1},
doi = {10.1002/cam4.6764}
}
EUVIMED